EDESA BIOTECH, INC. (EDSA) Scorecard
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Lose.
13/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 3 wins, 9 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
WinEDSA / S&P 55.45% / 15.20% |
LoseEDSA / S&P EDSA unavailable / 15.00% |
LoseEDSA / S&P EDSA unavailable / 50.40% |
| 2026-Q11/3 |
WinEDSA / S&P 268.31% / -4.33% |
LoseEDSA / S&P EDSA unavailable / 11.30% |
LoseEDSA / S&P EDSA unavailable / 27.70% |
| 2025-Q40/3 |
LoseEDSA / S&P -42.51% / 2.65% |
LoseEDSA / S&P EDSA unavailable / 9.00% |
LoseEDSA / S&P EDSA unavailable / 13.40% |
| 2025-Q31/3 |
WinEDSA / S&P 21.67% / 8.12% |
LoseEDSA / S&P EDSA unavailable / 4.61% |
LoseEDSA / S&P EDSA unavailable / 13.45% |
| 2025-Q20/3 |
LoseEDSA / S&P -16.80% / 10.94% |
LoseEDSA / S&P EDSA unavailable / 4.83% |
LoseEDSA / S&P EDSA unavailable / 10.63% |
| 2025-Q11/3 |
WinEDSA / S&P 45.24% / -4.27% |
LoseEDSA / S&P EDSA unavailable / 4.98% |
LoseEDSA / S&P EDSA unavailable / 10.57% |
| 2024-Q40/3 |
LoseEDSA / S&P -62.25% / 2.41% |
LoseEDSA / S&P EDSA unavailable / 5.25% |
LoseEDSA / S&P EDSA unavailable / 6.15% |
| 2024-Q30/3 |
LoseEDSA / S&P 3.97% / 5.89% |
LoseEDSA / S&P EDSA unavailable / 5.89% |
LoseEDSA / S&P EDSA unavailable / 6.11% |
| 2024-Q20/3 |
LoseEDSA / S&P 2.15% / 4.28% |
LoseEDSA / S&P EDSA unavailable / 5.38% |
LoseEDSA / S&P EDSA unavailable / 5.12% |
| 2024-Q10/3 |
LoseEDSA / S&P -8.32% / 10.56% |
LoseEDSA / S&P EDSA unavailable / 5.71% |
LoseEDSA / S&P EDSA unavailable / 5.59% |
| 2023-Q40/3 |
LoseEDSA / S&P 3.63% / 11.69% |
LoseEDSA / S&P EDSA unavailable / 6.81% |
LoseEDSA / S&P EDSA unavailable / 7.78% |
| 2023-Q30/3 |
LoseEDSA / S&P -22.22% / -3.27% |
LoseEDSA / S&P EDSA unavailable / 7.52% |
LoseEDSA / S&P EDSA unavailable / -5.03% |
| 2023-Q20/3 |
LoseEDSA / S&P -10.99% / 8.74% |
LoseEDSA / S&P EDSA unavailable / 9.50% |
LoseEDSA / S&P EDSA unavailable / -8.57% |
| 2023-Q10/3 |
LoseEDSA / S&P -57.87% / 7.50% |
LoseEDSA / S&P EDSA unavailable / 10.77% |
LoseEDSA / S&P EDSA unavailable / -15.69% |
| 2022-Q41/3 |
WinEDSA / S&P 134.78% / 7.56% |
LoseEDSA / S&P EDSA unavailable / 11.88% |
LoseEDSA / S&P EDSA unavailable / -17.99% |
| 2022-Q30/3 |
LoseEDSA / S&P -42.86% / -4.88% |
LoseEDSA / S&P EDSA unavailable / 13.47% |
LoseEDSA / S&P EDSA unavailable / -1.41% |
| 2022-Q20/3 |
LoseEDSA / S&P -45.79% / -16.10% |
LoseEDSA / S&P EDSA unavailable / 13.71% |
LoseEDSA / S&P EDSA unavailable / 11.04% |
| 2022-Q10/3 |
LoseEDSA / S&P -47.25% / -4.60% |
LoseEDSA / S&P EDSA unavailable / 15.97% |
LoseEDSA / S&P EDSA unavailable / 42.23% |
| 2021-Q40/3 |
LoseEDSA / S&P -23.71% / 11.03% |
LoseEDSA / S&P EDSA unavailable / 15.00% |
LoseEDSA / S&P EDSA unavailable / 96.40% |
| 2021-Q31/3 |
WinEDSA / S&P 39.77% / 0.58% |
LoseEDSA / S&P -100.00% / 10.77% |
LoseEDSA / S&P EDSA unavailable / 69.42% |
| 2021-Q20/3 |
LoseEDSA / S&P -2.22% / 8.55% |
LoseEDSA / S&P EDSA unavailable / 6.58% |
LoseEDSA / S&P EDSA unavailable / 51.81% |
| 2021-Q11/3 |
WinEDSA / S&P 27.06% / 6.17% |
LoseEDSA / S&P EDSA unavailable / -1.06% |
LoseEDSA / S&P EDSA unavailable / 7.39% |
| 2020-Q40/3 |
LoseEDSA / S&P -47.34% / 12.15% |
LoseEDSA / S&P EDSA unavailable / -3.72% |
LoseEDSA / S&P EDSA unavailable / -33.42% |
| 2020-Q31/3 |
WinEDSA / S&P 64.36% / 8.93% |
LoseEDSA / S&P EDSA unavailable / -2.04% |
LoseEDSA / S&P EDSA unavailable / -27.10% |
| 2020-Q21/3 |
WinEDSA / S&P 129.44% / 20.54% |
LoseEDSA / S&P EDSA unavailable / -0.46% |
LoseEDSA / S&P EDSA unavailable / -27.11% |
| 2020-Q10/3 |
LoseEDSA / S&P -47.80% / -19.60% |
LoseEDSA / S&P EDSA unavailable / 3.47% |
LoseEDSA / S&P EDSA unavailable / -14.75% |
| 2019-Q40/3 |
LoseEDSA / S&P -34.19% / 9.07% |
LoseEDSA / S&P EDSA unavailable / 5.36% |
LoseEDSA / S&P EDSA unavailable / 2.99% |
| 2019-Q30/3 |
LoseEDSA / S&P -11.51% / 1.70% |
LoseEDSA / S&P EDSA unavailable / 5.02% |
LoseEDSA / S&P EDSA unavailable / 0.21% |
| 2019-Q21/3 |
WinEDSA / S&P 7.65% / 4.30% |
LoseEDSA / S&P -99.41% / 6.64% |
LoseEDSA / S&P EDSA unavailable / 8.65% |
| 2019-Q11/3 |
WinEDSA / S&P 19.78% / 13.65% |
LoseEDSA / S&P -100.00% / 8.12% |
LoseEDSA / S&P EDSA unavailable / 14.29% |
| 2018-Q40/3 |
LoseEDSA / S&P -34.53% / -13.52% |
LoseEDSA / S&P -23.30% / 9.05% |
LoseEDSA / S&P EDSA unavailable / 18.23% |
| 2018-Q30/3 |
LoseEDSA / S&P -22.78% / 7.71% |
LoseEDSA / S&P -58.74% / 10.21% |
LoseEDSA / S&P EDSA unavailable / 19.06% |
| 2018-Q20/3 |
LoseEDSA / S&P -68.64% / 3.43% |
LoseEDSA / S&P -82.42% / 9.03% |
LoseEDSA / S&P EDSA unavailable / 14.46% |
| 2018-Q11/3 |
WinEDSA / S&P 1.23% / -0.76% |
LoseEDSA / S&P -87.23% / 7.68% |
LoseEDSA / S&P EDSA unavailable / 12.46% |
| 2017-Q40/3 |
LoseEDSA / S&P -28.32% / 6.64% |
LoseEDSA / S&P -90.98% / 7.03% |
LoseEDSA / S&P EDSA unavailable / 13.82% |
| 2017-Q30/3 |
LoseEDSA / S&P -7.38% / 4.48% |
LoseEDSA / S&P -83.89% / 5.68% |
LoseEDSA / S&P EDSA unavailable / 17.57% |
| 2017-Q20/3 |
LoseEDSA / S&P -25.15% / 3.09% |
LoseEDSA / S&P -59.79% / 4.83% |
LoseEDSA / S&P EDSA unavailable / 17.74% |
| 2017-Q10/3 |
LoseEDSA / S&P -19.70% / 6.07% |
LoseEDSA / S&P -43.55% / 3.67% |
LoseEDSA / S&P EDSA unavailable / 13.32% |
| 2016-Q40/3 |
LoseEDSA / S&P -15.42% / 3.82% |
LoseEDSA / S&P -10.52% / 2.09% |
LoseEDSA / S&P EDSA unavailable / 7.05% |
| 2016-Q31/3 |
LoseEDSA / S&P -37.17% / 3.85% |
WinEDSA / S&P 67.62% / 0.20% |
LoseEDSA / S&P EDSA unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | EDSA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 98.28% | 20.78% |
| Annualized return | 98.28% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | EDSA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -89.26% | 83.14% |
| Annualized return | -36.00% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | EDSA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.38% | 319.30% |
| Annualized return | -39.84% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B |